Bediol vs Bedrocan: UK Pharmacist Study on Patient-Reported Efficacy
A UK-wide survey of specialist pharmacists and their patients has compared patient-reported outcomes for two of the most commonly prescribed whole-flower cannabis products in the UK.
A survey-based study conducted through a network of UK specialist pharmacies has compared patient-reported outcomes for Bediol and Bedrocan, the two most commonly dispensed whole-flower cannabis-based medicinal products in the United Kingdom. The research involved pharmacists at 34 dispensing sites and 820 patient respondents.
Product Profiles
Bediol is a balanced-ratio product with approximately equal concentrations of THC and CBD, standardised for vaporisation or preparation as a tea infusion. Bedrocan contains a substantially higher THC concentration with minimal CBD content and is intended primarily for inhalation via medical vaporiser.
Patient-Reported Outcomes by Indication
- For chronic neuropathic pain: Bedrocan reported as more effective by 58% of patients in that indication group
- For anxiety and sleep: Bediol preferred by 71% of patients due to perceived lower psychoactive intensity
- For spasticity related to MS: outcomes broadly comparable between products
- Adverse effect profiles differed, with Bedrocan associated with higher rates of transient anxiety in first-time users
Pharmacist Perspectives
Participating pharmacists noted that product choice in clinical practice is frequently constrained by supply availability rather than purely by clinical preference. Several respondents highlighted the need for more consistent stock availability across the UK distribution network.
"Our patients are not interchangeable with each other, and neither are these products. A study like this gives practitioners the evidence base to have more nuanced conversations about product selection."
The study authors acknowledged the inherent limitations of self-reported outcome data and called for prospective registry-linked follow-up to validate the findings.
